Jean-FranÃ§ois Mouscadet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12097990/publications.pdf

Version: 2024-02-01

84	4,284	94433	110387
papers	citations	37 h-index	64 g-index

92	92	92	3574
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pyridoxine hydroxamic acids as novel HIV-integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1233-1236.	2.2	9
2	Biochemical properties of the xenotropic murine leukemia virus-related virus integrase. Biochimie, 2014, 107, 300-309.	2.6	0
3	A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: From nucleocapsid-condensed RNA to Vpr-bridged DNA. Virus Research, 2013, 171, 287-303.	2.2	25
4	Impact of the Ku Complex on HIV-1 Expression and Latency. PLoS ONE, 2013, 8, e69691.	2.5	22
5	3â€² Self-Inactivating Long Terminal Repeat Inserts for the Modulation of Transgene Expression from Lentiviral Vectors. Human Gene Therapy Methods, 2012, 23, 84-97.	2.1	7
6	In SilicoandIn VitroComparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. Advances in Virology, 2012, 2012, 1-13.	1.1	6
7	Structureâ€“Activity Relationship Studies of HIV-1 Integrase Oligonucleotide Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 532-537.	2.8	7
8	Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antiviral Therapy, 2011, 16, 937-940.	1.0	8
9	Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: New structural insight into the HIV-1 integrase inhibition. European Journal of Medicinal Chemistry, 2011, 46, 1749-1756.	5.5	25
10	G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not. Retrovirology, 2011, 8, 68.	2.0	24
11	Ethyl malonate amides: A diketo acid offspring fragment for HIV integrase inhibition. Bioorganic and Medicinal Chemistry, 2011, 19, 5000-5005.	3.0	9
12	Synthesis of benzo-, pyrido-, thieno- and imidazo-fused N-hydroxy-4-oxopyrimidine-2-carboxylic acid derivatives. Tetrahedron Letters, 2011, 52, 753-756.	1.4	1
13	Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. Journal of Experimental Medicine, 2011, 208, 1823-1834.	8.5	156
14	Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir. Antimicrobial Agents and Chemotherapy, 2011, 55, 1293-1295.	3.2	29
15	Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors. Molecules, 2010, 15, 3048-3078.	3.8	51
16	Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2010, 54, 491-501.	3.2	74
17	A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain. Nucleic Acids Research, 2010, 38, 3692-3708.	14.5	25
18	Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resistance Updates, 2010, 13, 139-150.	14.4	68

#	Article	IF	Citations
19	Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 63, 795-804.	3.0	91
20	HIVâ€1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. Journal of Molecular Recognition, 2009, 22, 480-494.	2.1	17
21	Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO Journal, 2009, 28, 980-991.	7.8	91
22	Synthesis and anti-HIV-1 integrase activity of modified dinucleotides. European Journal of Medicinal Chemistry, 2009, 44, 5029-5044.	5.5	6
23	Structural and theoretical studies of integrase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4806-4809.	2.2	8
24	Structural basis for HIV-1 DNA integration in the human genome. Retrovirology, 2009, 6, P79.	2.0	1
25	Raltegravir: molecular basis of its mechanism of action. European Journal of Medical Research, 2009, 14, 5.	2.2	29
26	Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antiviral Therapy, 2009, 14, 123-129.	1.0	38
27	Structural effects of amino acid variations between B and CRF02â€AG HIVâ€1 integrases. Journal of Medical Virology, 2008, 80, 754-761.	5.0	20
28	Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones. European Journal of Medicinal Chemistry, 2008, 43, 1222-1229.	5.5	28
29	The total synthesis of fukiic acid, an HIV-1 integrase inhibitor. European Journal of Medicinal Chemistry, 2008, 43, 2268-2271.	5.5	10
30	Synthesis and antiviral properties of some polyphenols related to Salvia genus. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4736-4740.	2.2	25
31	Reaction of Rosmarinic Acid with Nitrite Ions in Acidic Conditions: Discovery of Nitro- and Dinitrorosmarinic Acids as New Anti-HIV-1 Agents. Journal of Medicinal Chemistry, 2008, 51, 2575-2579.	6.4	66
32	Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology, 2008, 5, 114.	2.0	177
33	Design, Synthesis, and Biological Evaluation of a Series of 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain. Journal of Medicinal Chemistry, 2008, 51, 7717-7730.	6.4	115
34	Insight into the Integrase-DNA Recognition Mechanism. Journal of Biological Chemistry, 2008, 283, 27838-27849.	3.4	45
35	The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Research, 2008, 37, 1193-1201.	14.5	128
36	Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrobial Agents and Chemotherapy, 2008, 52, 1351-1358.	3.2	256

#	Article	IF	Citations
37	Ku80 Participates in the Targeting of Retroviral Transgenes to the Chromatin of CHO Cells. Journal of Virology, 2007, 81, 7924-7932.	3.4	15
38	Synthesis and HIV-1 Integrase Inhibition of Novel Bis- or Tetra-Coumarin Analogues. Chemical and Pharmaceutical Bulletin, 2007, 55, 1740-1743.	1.3	31
39	Target Recognition by Catechols and Î²-Ketoenols:â€‰ Potential Contribution of Hydrogen Bonding and Mn/Mg Chelation to HIV-1 Integrase Inhibition. Journal of Medicinal Chemistry, 2007, 50, 1133-1145.	6.4	40
40	Efficient and Specific Internal Cleavage of a Retroviral Palindromic DNA Sequence by Tetrameric HIV-1 Integrase. PLoS ONE, 2007, 2, e608.	2.5	31
41	HIV-1 Integrase Inhibition of Biscoumarin Analogues. Chemical and Pharmaceutical Bulletin, 2006, 54, 682-686.	1.3	67
42	Kinetic study of the HIV-1 DNA 3'-end processing. Single-turnover property of integrase. FEBS Journal, 2006, 273, 1137-1151.	4.7	39
43	Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1005-1009.	2.2	18
44	Relationship between the Oligomeric Status of HIV-1 Integrase on DNA and Enzymatic Activity. Journal of Biological Chemistry, 2006, 281, 22707-22719.	3.4	138
45	Inhibition of Early Steps of HIV-1 Replication by SNF5/Ini1. Journal of Biological Chemistry, 2006, 281, 22736-22743.	3.4	42
46	Probing of HIV-1 Integrase/DNA Interactions Using Novel Analogs of Viral DNA. Journal of Biological Chemistry, 2006, 281, 11530-11540.	3.4	39
47	HIV-1 replication inhibitors of the styrylquinoline class: introduction of an additional carboxyl group at the C-5 position of the quinoline. Tetrahedron Letters, 2005, 46, 2201-2205.	1.4	70
48	New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: Synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4019-4022.	2.2	59
49	Synthesis and HIV-1 integrase inhibitory activities of caffeic acid dimers derived from Salvia officinalis. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5053-5056.	2.2	29
50	New HIV-1 Replication Inhibitors of the Styryquinoline Class Bearing Aroyl/Acyl Groups at the C-7 Position: Synthesis and Biological Activity.. ChemInform, 2005, 36, no.	0.0	0
51	Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase, RNase H, and Integrase Activities by Hydroxytropolones. Antimicrobial Agents and Chemotherapy, 2005, 49, 4884-4894.	3.2	78
52	A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles. Retrovirology, 2005, 2, 31.	2.0	25
53	Nuclear Import of HIV-1 Integrase Is Inhibited in Vitro by Styrylquinoline Derivatives. Molecular Pharmacology, 2004, 66, 783-788.	2.3	53
54	Mechanism of HIV-1 Integrase Inhibition by Styrylquinoline Derivatives in Vitro. Molecular Pharmacology, 2004, 65, 85-98.	2.3	80

#	Article	IF	Citations
55	Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2473-2476.	2.2	85
56	HIV-1 integrase can process a 3â€²-end crosslinked substrate. FEBS Journal, 2004, 271, 205-211.	0.2	9
57	HIV-1 Integrase Complexes with DNA Dissociate in the Presence of Short Oligonucleotides Conjugated to Acridineâ€. Biochemistry, 2004, 43, 8735-8743.	2.5	31
58	Chemical Modification of Coumarin Dimer and HIV-1 Integrase Inhibitory Activity.. ChemInform, 2003, 34, no.	0.0	0
59	Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections. Bioorganic and Medicinal Chemistry, 2003, 11, 5013-5023.	3.0	174
60	The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. Nucleic Acids Research, 2003, 31, 2694-2702.	14.5	20
61	The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1. Journal of Virology, 2003, 77, 12507-12522.	3.4	69
62	Disulfide-Linked Integrase Oligomers Involving C280 Residues Are Formed In Vitro and In Vivo but Are Not Essential for Human Immunodeficiency Virus Replication. Journal of Virology, 2003, 77, 135-141.	3.4	21
63	Ku Represses the HIV-1 Transcription. Journal of Biological Chemistry, 2002, 277, 4918-4924.	3.4	35
64	Chemical Modification of Coumarin Dimer and HIV-1 Integrase Inhibitory Activity.. Chemical and Pharmaceutical Bulletin, 2002, 50, 1634-1637.	1.3	57
65	Disruption of HIV-1 Integraseâ€'DNA Complexes by Short 6-Oxocytosine-Containing Oligonucleotides,. Biochemistry, 2002, 41, 1529-1538.	2.5	22
66	Use of the Kohonen Neural Network for Rapid Screening of Ex Vivo Anti-HIV Activity of Styrylquinolines. Journal of Medicinal Chemistry, 2002, 45, 4647-4654.	6.4	82
67	Effect of Ku80 Depletion on the Preintegrative Steps of HIV-1 Replication in Human Cells. Virology, 2002, 300, 100-108.	2.4	72
68	HIV-1 Integrase Catalytic Core: Molecular Dynamics and Simulated Fluorescence Decays. Biophysical Journal, 2001, 81, 473-489.	0.5	27
69	Spectroscopy and photophysics of styrylquinoline-type HIV-1 integrase inhibitors and its oxidized forms studied by steady state and time resolved absorption and fluorescence. Physical Chemistry Chemical Physics, 2001, 3, 3797-3804.	2.8	8
70	Peptide Inhibitors of HIV-1 Integrase Dissociate the Enzyme Oligomers. Biochemistry, 2001, 40, 13840-13848.	2.5	86
71	Inhibition of HIV Integrase by 4-Hydroxycoumarin Dimer Bearing Aniline Mustard Moiety. Heterocycles, 2001, 55, 1263.	0.7	6
72	HIV-1 replication inhibitors of the styrylquinoline class: incorporation of a masked diketo acid pharmacophore. Tetrahedron Letters, 2001, 42, 8189-8192.	1.4	37

#	Article	IF	Citations
73	Synthesis and hiv-1 integrase inhibitory activities of catechol and bis-Catechol derivatives. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3175-3178.	2.2	31
74	Interactions of the C-terminus of viral protein R with nucleic acids are modulated by its N-terminus. FEBS Journal, 2000, 267, 3654-3660.	0.2	32
75	Structureâ^'Activity Relationships and Binding Mode of Styrylquinolines as Potent Inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture. Journal of Medicinal Chemistry, 2000, 43, 1533-1540.	6.4	150
76	Modeling of the Inhibition of Retroviral Integrases by Styrylquinoline Derivatives. Journal of Medicinal Chemistry, 2000, 43, 1949-1957.	6.4	64
77	Determinants of Mg2+-Dependent Activities of Recombinant Human Immunodeficiency Virus Type 1 Integraseâ€. Biochemistry, 2000, 39, 9285-9294.	2.5	123
78	Oligomeric States of the HIV-1 Integrase As Measured by Time-Resolved Fluorescence Anisotropyâ€. Biochemistry, 2000, 39, 9275-9284.	2.5	135
79	Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase. FEBS Letters, 1999, 460, 270-274.	2.8	10
80	Inhibition of HIV-1 Integration by Mono- & Bifunctionalized Triple Helix Forming Oligonucleotides. Nucleosides & Nucleotides, 1999, 18, 1717-1718.	0.5	1
81	Antisense-mediated Repression of DNA Topoisomerase II Expression Leads To an Impairment of HIV-1 Replicative Cycle. Journal of Molecular Biology, 1999, 285, 945-954.	4.2	14
82	Styrylquinoline Derivatives:Â A New Class of Potent HIV-1 Integrase Inhibitors That Block HIV-1 Replication in CEM Cells. Journal of Medicinal Chemistry, 1998, 41, 2846-2857.	6.4	223
83	Alternate Strand DNA Triple Helix-mediated Inhibition of HIV-1 U5 Long Terminal Repeat Integration in Vitro. Journal of Biological Chemistry, 1996, 271, 10359-10364.	3.4	43
84	Triple Helix Formation with Short Oligonucleotide-Intercalator Conjugates Matching the HIV-1 U3 LTR End Sequence. Biochemistry, 1994, 33, 4187-4196.	2.5	65